mk 0663 has been researched along with dinoprostone in 17 studies
| Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (dinoprostone) | Trials (dinoprostone) | Recent Studies (post-2010) (dinoprostone) |
|---|---|---|---|---|---|
| 549 | 173 | 265 | 29,105 | 1,346 | 6,357 |
| Protein | Taxonomy | mk 0663 (IC50) | dinoprostone (IC50) |
|---|---|---|---|
| Prostaglandin E2 receptor EP1 subtype | Homo sapiens (human) | 0.0155 | |
| Prostaglandin E2 receptor EP4 subtype | Homo sapiens (human) | 0.0031 | |
| Prostaglandin E2 receptor EP4 subtype | Rattus norvegicus (Norway rat) | 0.0021 | |
| Prostaglandin E2 receptor EP3 subtype | Homo sapiens (human) | 0.002 | |
| Prostaglandin E2 receptor EP2 subtype | Homo sapiens (human) | 0.0087 | |
| Prostacyclin receptor | Homo sapiens (human) | 0.26 | |
| Prostaglandin E2 receptor EP2 subtype | Rattus norvegicus (Norway rat) | 0.0052 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 4 (23.53) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, N; Dallob, A; De Schepper, P; DeTora, L; Gertz, B; Gottesdiener, K; Greenberg, H; Hawkey, CJ; Wagner, J; Waldman, S; Wight, N; Wong, P | 1 |
| Bretschneider, E; Censarek, P; Fischer, JW; Meyer-Kirchrath, J; Pape, R; Rabausch, K; Sarbia, M; Schrör, K; Weber, AA | 1 |
| Geisslinger, G; Manderscheid, C; Niederberger, E | 1 |
| Abdalla, GK; Castro, EC; Faria, GE; Michelin, MA; Reis, MA; Silva, KT | 1 |
| Cavanaugh, PF; Chappell, DL; Dallob, AL; Flynn, ME; Hilliard, DA; Larson, PJ; Laterza, OF; Miller, J; Royalty, J; Schwartz, JI; Snyder, KM; Wagner, JA | 1 |
| Azoubel, E; Azoubel, MC; Bittencourt, S; Brito, GA; Cangussú, V; Cunha, FQ; Ribeiro, RA; Sarmento, VA | 1 |
| Sharma, P; Suresh, S | 1 |
| Anauate, MC; de Mello, SB; Torres, LM | 1 |
| Calvello, R; Carbone, ML; Cianciulli, A; Malerba, P; Panaro, MA; Perrone, MG; Scilimati, A; Vitale, P | 1 |
| Antoniazzi, MM; Barbaro, KC; Faquim-Mauro, EL; Jared, SG; Kimura, LF; Pereira, NA; Prezotto-Neto, JP; Santoro, ML; Távora, BC; Teixeira, CF | 1 |
| Ghosh, T; Sil, S | 1 |
| Li, Z; Wang, D; Wang, S; Yang, Q; Yang, Y | 1 |
| Fu, WZ; He, JW; Hu, YQ; Li, SS; Liu, YJ; Zhang, ZL | 1 |
| Agnes, JP; Báfica, A; Bishop, AJR; Bruxel, MA; Casagrande, T; Cassali, GD; das Neves, RN; Delgobo, M; Falchetti, M; Garcia, APV; Gelain, DP; Gonçalves, RM; Mendes, DAGB; Moreira, JCF; Rafacho, A; Somensi, N; Vieira, TC; Zanotto-Filho, A | 1 |
| Kleszcz, R; Krajka-Kuźniak, V; Kruhlenia, N; Majchrzak-Celińska, A; Misiorek, JO; Przybyl, L; Rolle, K | 1 |
| Abo-Youssef, A; Ahmed, O; Ali, G; Hersi, F; Mohamed, W; Omar, H | 1 |
| Gorbach, T; Koiro, O; Kudina, O; Shtrygol, S; Tovchiga, O; Yudkevich, T | 1 |
4 trial(s) available for mk 0663 and dinoprostone
| Article | Year |
|---|---|
Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cyclooxygenase 2; Dinoprostone; Double-Blind Method; Drug Tolerance; Etoricoxib; Female; Gastric Mucosa; Humans; Isoenzymes; Lipopolysaccharides; Male; Membrane Proteins; Middle Aged; Naproxen; Platelet Aggregation; Prostaglandin-Endoperoxide Synthases; Pyridines; Sulfones | 2003 |
Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cross-Over Studies; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Humans; Male; Middle Aged; Pyrazoles; Pyridines; Sulfonamides; Sulfones; Thromboxane B2 | 2008 |
Adjunctive benefits of systemic etoricoxib in non-surgical treatment of aggressive periodontitis: short-term evaluation.
Topics: Adolescent; Adult; Alveolar Bone Loss; Combined Modality Therapy; Cyclooxygenase Inhibitors; Dental Scaling; Dinoprostone; Double-Blind Method; Etoricoxib; Female; Follow-Up Studies; Gingival Crevicular Fluid; Gingival Hemorrhage; Humans; Male; Periodontal Attachment Loss; Periodontal Pocket; Periodontitis; Pilot Projects; Placebos; Pyridines; Root Planing; Sulfones; Tooth Cervix | 2008 |
Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention.
Topics: Adult; Asian People; China; Dinoprostone; Etoricoxib; Family; Female; Humans; Male; Middle Aged; Organic Anion Transporters; Osteoarthropathy, Primary Hypertrophic; Prospective Studies; Pyridines; Sulfones | 2017 |
13 other study(ies) available for mk 0663 and dinoprostone
| Article | Year |
|---|---|
Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins.
Topics: Alprostadil; Blood Coagulation; Bucladesine; Carotid Artery Diseases; Carotid Artery, Internal; Cells, Cultured; Colforsin; Coronary Vessels; Culture Media, Serum-Free; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Epoprostenol; Etoricoxib; Gene Expression Profiling; Gene Expression Regulation; Humans; Iloprost; Isoquinolines; Mammary Arteries; Membrane Proteins; Models, Biological; Myocytes, Smooth Muscle; Oligonucleotide Array Sequence Analysis; Prostaglandin-Endoperoxide Synthases; Prostaglandins; Pyridines; Receptors, Prostaglandin; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP3 Subtype; RNA, Messenger; Saphenous Vein; Second Messenger Systems; Sulfonamides; Sulfones; Tetradecanoylphorbol Acetate; Thrombomodulin; Thrombophilia; Vasodilator Agents | 2005 |
Different COX-independent effects of the COX-2 inhibitors etoricoxib and lumiracoxib.
Topics: Animals; Cell Nucleus; Cell Proliferation; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Diclofenac; Dinoprostone; Etoricoxib; Gene Expression Regulation; Macrophages; Mice; NF-kappa B; Nitric Oxide Synthase Type II; Nitrites; Organic Chemicals; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-jun; Pyridines; Sulfones; Transcription Factor AP-1 | 2006 |
Trypanosoma cruzi: the role of PGE2 in immune response during the acute phase of experimental infection.
Topics: Acute Disease; Animals; Cells, Cultured; Chagas Disease; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Fibrosis; Male; Meloxicam; Mice; Mice, Inbred BALB C; Myocardium; Parasitemia; Prostaglandins; Pyridines; Spleen; Sulfones; Thiazines; Thiazoles; Trypanosoma cruzi | 2008 |
Influence of COX-2-induced PGE2 on the initiation and progression of tail regeneration in Northern House Gecko, Hemidactylus flaviviridis.
Topics: Animals; Celecoxib; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Lizards; Male; Pyrazoles; Pyridines; Regeneration; Sulfonamides; Sulfones; Tail | 2008 |
Effect of isolated fractions of Harpagophytum procumbens D.C. (devil's claw) on COX-1, COX-2 activity and nitric oxide production on whole-blood assay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Blood Chemical Analysis; Blood Coagulation; Blood Platelets; Cinnamates; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dinoprostone; Etoricoxib; Female; Glycosides; Harpagophytum; Humans; Indomethacin; Inflammation Mediators; Iridoids; Lipopolysaccharides; Nitric Oxide; Plant Extracts; Pyrans; Pyridines; Sulfones; Thromboxane B2 | 2010 |
Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.
Topics: Animals; Aspirin; Celecoxib; Cell Line; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Dose-Response Relationship, Drug; Down-Regulation; Etoricoxib; I-kappa B Proteins; Inflammation Mediators; Intramolecular Oxidoreductases; Lipopolysaccharides; Membrane Proteins; Mice; Microglia; NF-kappa B; NF-KappaB Inhibitor alpha; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphorylation; Prostaglandin-E Synthases; Pyrazoles; Pyridines; RNA, Messenger; Sulfonamides; Sulfones | 2012 |
Mast cells and histamine play an important role in edema and leukocyte recruitment induced by Potamotrygon motoro stingray venom in mice.
Topics: Animals; Cell Line, Tumor; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2 Inhibitors; Dinoprostone; Edema; Elasmobranchii; Etoricoxib; Fish Venoms; Histamine; Histamine H1 Antagonists; Leukocytes; Male; Mast Cells; Membrane Proteins; Mice; Promethazine; Prostaglandin D2; Pyridines; Rats; Sulfones | 2015 |
Role of cox-2 mediated neuroinflammation on the neurodegeneration and cognitive impairments in colchicine induced rat model of Alzheimer's Disease.
Topics: Alzheimer Disease; Analysis of Variance; Animals; Cognition Disorders; Colchicine; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cytokines; Dinoprostone; Disease Models, Animal; Dose-Response Relationship, Drug; Encephalitis; Etoricoxib; Injections, Intraventricular; Male; Maze Learning; Neurodegenerative Diseases; Plaque, Amyloid; Pyridines; Rats; Sulfones; Time Factors | 2016 |
Successful treatment of pachydermoperiostosis with etoricoxib in a patient with a homozygous splice-site mutation in the SLCO2A1 gene.
Topics: Adult; Cyclooxygenase 2 Inhibitors; Dinoprostone; Etoricoxib; Homozygote; Humans; Male; Mutation; Organic Anion Transporters; Osteoarthropathy, Primary Hypertrophic; RNA Splice Sites; Treatment Outcome | 2019 |
COX-2 promotes mammary adipose tissue inflammation, local estrogen biosynthesis, and carcinogenesis in high-sugar/fat diet treated mice.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Aromatase; Breast Neoplasms; Cell Line, Tumor; Chemokine CCL2; Cyclooxygenase 2; Diet, High-Fat; Dinoprostone; Disease Models, Animal; Etoricoxib; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; MCF-7 Cells; Medroxyprogesterone Acetate; Mice; Sugars; Up-Regulation | 2021 |
COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/β-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
Topics: Aged; Antineoplastic Agents, Alkylating; Apoptosis; beta Catenin; Brain Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; DNA Modification Methylases; DNA Repair Enzymes; Dose-Response Relationship, Drug; Etoricoxib; Female; Glioblastoma; Humans; Isoxazoles; Lactones; Male; Methylation; Middle Aged; Neoplasm Proteins; Pyrazoles; Receptors, Prostaglandin E, EP4 Subtype; Sulfonamides; Sulfones; Temozolomide; Tumor Suppressor Proteins; Wnt Signaling Pathway | 2021 |
The Protective Role of Etoricoxib Against Diethylnitrosamine/2-acetylaminofluorene- Induced Hepatocarcinogenesis in Wistar Rats: The Impact of NF-κB/COX-2/PGE2 Signaling.
Topics: 2-Acetylaminofluorene; Animals; Carcinoma, Hepatocellular; Cyclooxygenase 2; Diethylnitrosamine; Dinoprostone; Etoricoxib; Female; Humans; Liver Neoplasms; Male; NF-kappa B; Rats; Rats, Wistar | 2022 |
The effect of non-steroidal anti-inflammatory drugs with different mechanisms of action on the body temperature and cyclooxygenase pathway of the arachidonic acid cascade on the model of acute general cooling (air hypothermia) in rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Body Temperature; Cyclooxygenase 2; Diclofenac; Dinoprost; Dinoprostone; Etoricoxib; Hypothermia; Rats | 2022 |